Sherri-Ann M Burnett-Bowie

List of Publications by Year
in descending order

57 papers	4,542 citations	196777 29 h-index	182931 54 g-index
58 all docs	58 docs citations	58 times ranked	5065 citing authors

#	Article	IF	Citations
1	Associations of Age at Menopause With Postmenopausal Bone Mineral Density and Fracture Risk in Women. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e561-e569.	1.8	15
2	Using a Virtual Platform to Teach Residents How to Respond to Bias. Journal of General Internal Medicine, 2022, 37, 2871-2872.	1.3	5
3	Disparities in osteoporosis care among postmenopausal women in the United States. Maturitas, 2022, 156, 25-29.	1.0	13
4	Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Womenâ€™s Health Across the Nation (SWAN). Women's Midlife Health, 2022, 8, 3.	0.5	22
5	Attitudes and Actions Related to Racism: the Anti-RaCism (ARC) Survey Study. Journal of General Internal Medicine, 2022, 37, 2337-2344.	1.3	6
6	Association Between Resident Race and Ethnicity and Clinical Performance Assessment Scores in Graduate Medical Education. Academic Medicine, 2022, 97, 1351-1359.	0.8	19
7	Correspondence. Annals of Emergency Medicine, 2021, 77, 382-383.	0.3	0
8	The USPSTF 2021 Recommendations on Screening for Asymptomatic Vitamin D Deficiency in Adults. JAMA - Journal of the American Medical Association, 2021, 325, 1401.	3.8	8
9	Changes in Regional Fat Distribution and Anthropometric Measures Across the Menopause Transition. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2520-2534.	1.8	23
10	Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay. PLoS ONE, 2021, 16, e0254158.	1.1	5
11	Effect of Physician-Delivered COVID-19 Public Health Messages and Messages Acknowledging Racial Inequity on Black and White Adultsâ€™ Knowledge, Beliefs, and Practices Related to COVID-19. JAMA Network Open, 2021, 4, e2117115.	2.8	27
12	This is our lane: talking with patients about racism. Women's Midlife Health, 2021, 7, 7.	0.5	15
13	Racism: the shameful practices that the medical profession is finally addressing. Women's Midlife Health, 2021, 7, 9.	0.5	3
14	Addressing the Elephant in the Room: Microaggressions in Medicine. Annals of Emergency Medicine, 2020, 76, 387-391.	0.3	46
15	Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2779-2788.	1.8	15
16	Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1862-e1871.	1.8	66
17	Age-Related Changes in Bone Density, Microarchitecture, and Strength in Postmenopausal Black and White Women: The SWAN Longitudinal HR-pQCT Study. Journal of Bone and Mineral Research, 2020, 37, 41-51.	3.1	7
18	Leadership & Professional Development: Breaking the Silence as a Bystander. Journal of Hospital Medicine, 2020, 15, 598-598.	0.7	0

#	Article	IF	Citations
19	Anti-Mullerian Hormone as Predictor of Future and Ongoing Bone Loss During the Menopause Transition. Journal of Bone and Mineral Research, 2020, 37, 1224-1232.	3.1	2
20	Serum Sex Hormones and the Risk of Fracture Across the Menopausal Transition: Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2412-2418.	1.8	9
21	Temporal increases in 25â€hydroxyvitamin D in midlife women: Longitudinal results from the Study of Womenâ€™s Health Across the Nation. Clinical Endocrinology, 2019, 91, 48-57.	1.2	6
22	Trabecular Bone Morphology Correlates With Skeletal Maturity and Body Composition in Healthy Adolescent Girls. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 336-345.	1.8	14
23	Bone Health During the Menopause Transition and Beyond. Obstetrics and Gynecology Clinics of North America, 2018, 45, 695-708.	0.7	97
24	Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2218-2229.	1.8	41
25	FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1151-1160.	1.8	24
26	Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. Journal of Clinical Densitometry, 2016, 19, 346-351.	0.5	29
27	Gonadal steroidâ€“dependent effects on bone turnover and bone mineral density in men. Journal of Clinical Investigation, 2016, 126, 1114-1125.	3.9	148
28	Teaching Medical Students How to Ask Patients Questions About Identity, Intersectionality, and Resilience. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2016, 12, 10422.	0.5	17
29	Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. Journal of Bone and Mineral Research, 2015, 30, 39-45.	3.1	121
30	Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2718-2723.	1.8	7
31	Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet, The, 2015, 386, 1147-1155.	6.3	403
32	Serum 25 Hydroxyvitamin D, Bone Mineral Density and Fracture Risk Across the Menopause. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2046-2054.	1.8	38
33	Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. American Journal of Clinical Nutrition, 2015, 102, 385-392.	2.2	33
34	Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1694-1700.	1.8	231
35	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 2013, 369, 1011-1022.	13.9	621
36	Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet, The, 2013, 382, 50-56.	6.3	384

#	Article	IF	Citations
37	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 2013, 369, 2455-2457.	13.9	61
38	Long-Term Follow-Up of Patients with Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4507-4514.	1.8	311
39	Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 624-631.	2.2	45
40	Prevalence and Predictors Ofvitamin D Deficiency in Healthy Adults. Endocrine Practice, 2012, 18, 914-923.	1.1	88
41	Bone and the Perimenopause. Obstetrics and Gynecology Clinics of North America, 2011, 38, 503-517.	0.7	34
42	The biology and pathology of vitamin D control in bone. Journal of Cellular Biochemistry, 2010, 111, 7-13.	1.2	55
43	Clinical Measures Identify Vitamin D Deficiency in Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 460-467.	2.2	78
44	Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2915-2921.	1.8	115
45	Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1097-1103.	1.8	22
46	Effects of aromatase inhibition in hypogonadal older men: a randomized, doubleâ€blind, placeboâ€controlled trial. Clinical Endocrinology, 2009, 70, 116-123.	1.2	57
47	Effects of hPTH(1-34) Infusion on Circulating Serum Phosphate, 1,25-Dihydroxyvitamin D, and FGF23 Levels in Healthy Men. Journal of Bone and Mineral Research, 2009, 24, 1681-1685.	3.1	71
48	Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4785-4792.	1.8	122
49	Effects of Teriparatide Retreatment in Osteoporotic Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2495-2501.	1.8	72
50	Vitamin D and fat. Menopause, 2009, 16, 637-638.	0.8	0
51	Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 660-661.	2.9	2
52	An Unusual Case of Primary Hyperparath Yroidism with Profoundly Elevated Parath Yroid Hormone Levels. Endocrine Practice, 2008, 14, 892-897.	1.1	4
53	Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone, 2007, 40, 913-918.	1.4	33
54	Post-transplant hypophosphatemia: Tertiary â€˜Hyper-Phosphatoninismâ€™?. Kidney International, 2006, 70, 1486-1494.	2.6	160

#	Article	IF	Citations
55	Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women. Journal of Bone and Mineral Research, 2006, 21, 1187-1196.	3.1	407
56	Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2882-2887.	1.8	130
57	Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2631-2637.	1.8	135